The FDA approved Wegovy HD, a higher-dose version of semaglutide (7.2mg) for weight loss and maintenance in adults with obesity. This approval came through the new National Priority Voucher program in just 54 days. Clinical data showed the higher dose produced greater average weight loss compared to standard doses, with similar blood sugar benefits for diabetic patients. Common side effects remained gastrointestinal, though altered skin sensations occurred more frequently at higher doses. This represents the fourth fast-tracked approval under the FDA's expedited review program for critical health priorities.
